PD-1/PD-L1 Immunotherapy Market Report

China PD-1/PD-L1 Immunotherapy Industry Market Research Report 2023-2029

  • POSTDATE：Sep 10, 2023
  • PAGES：209
  • REPORT CODE：GMM1785813
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the PD-1/PD-L1 Immunotherapy industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Jiangsu HengRui Medicine Co Ltd

    • Bristol-Myers Squibb Company

    • Sanofi SA

    • AstraZeneca Plc

    • F Hoffmann-La Roche Ltd

    • GlaxoSmithKline plc

    • Chia Tai Tianqing Pharmaceutical Group Co Ltd

    • Regeneron Pharmaceuticals Inc

    • Innovent Biologics Inc

    • BeiGene Ltd

    • Eli Lilly & Company

    • Novartis AG

    By Type:

    • PD-L1 Inhibitors

    • PD-1 Inhibitors

    By Application:

    • Small Cell Lung Cancer

    • Esophageal Cancer

    • Others

    • Non-Small Cell Lung Cancer

    • Urothelial Carcinoma

    • Hepatocellular Carcinoma

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China PD-1/PD-L1 Immunotherapy Market Overview 2018-2029

    • 1.1 China PD-1/PD-L1 Immunotherapy Industry Development Overview

    • 1.2 China PD-1/PD-L1 Immunotherapy Industry Development History

    • 1.3 China PD-1/PD-L1 Immunotherapy Industry Market Size (2018-2029)

    • 1.4 China PD-1/PD-L1 Immunotherapy Market Analysis by Type from Production Side

      • 1.4.1 China PD-1/PD-L1 Immunotherapy Production Volume, Production Value and Growth Rate of PD-L1 Inhibitors (2018-2029)

      • 1.4.2 China PD-1/PD-L1 Immunotherapy Production Volume, Production Value and Growth Rate of PD-1 Inhibitors (2018-2029)

    • 1.5 China PD-1/PD-L1 Immunotherapy Market Analysis by Application from Consumption End

      • 1.5.1 China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Small Cell Lung Cancer (2018-2029)

      • 1.5.2 China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Esophageal Cancer (2018-2029)

      • 1.5.3 China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

      • 1.5.4 China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Non-Small Cell Lung Cancer (2018-2029)

      • 1.5.5 China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Urothelial Carcinoma (2018-2029)

      • 1.5.6 China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Hepatocellular Carcinoma (2018-2029)

    • 1.6 China PD-1/PD-L1 Immunotherapy Market Analysis by Region

      • 1.6.1 North China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    Chapter 2 China PD-1/PD-L1 Immunotherapy Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on PD-1/PD-L1 Immunotherapy Market Status and Competition at home and abroad in 2023

      • 2.2.2 China PD-1/PD-L1 Immunotherapy Market Status and Competition Analysis in 2023

      • 2.2.3 China PD-1/PD-L1 Immunotherapy Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China PD-1/PD-L1 Immunotherapy Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on PD-1/PD-L1 Immunotherapy Industry Development

    Chapter 3 PD-1/PD-L1 ImmunotherapyIndustry Chain Analysis

    • 3.1 PD-1/PD-L1 Immunotherapy Industry Chain

    • 3.2 PD-1/PD-L1 Immunotherapy Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the PD-1/PD-L1 Immunotherapy Market

    • 3.3 PD-1/PD-L1 Immunotherapy Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the PD-1/PD-L1 Immunotherapy Market

    Chapter 4 China PD-1/PD-L1 Immunotherapy Market, by Type

    • 4.1 China PD-1/PD-L1 Immunotherapy Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China PD-1/PD-L1 Immunotherapy Total Production Volume and Growth Rate from Production Side

    • 4.5 China PD-1/PD-L1 Immunotherapy Production Volume and Growth Rate, by Type

      • 4.5.1 China PD-1/PD-L1 Immunotherapy Production Volume and Growth Rate of PD-L1 Inhibitors

      • 4.5.2 China PD-1/PD-L1 Immunotherapy Production Volume and Growth Rate of PD-1 Inhibitors

    Chapter 5 China PD-1/PD-L1 Immunotherapy Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China PD-1/PD-L1 Immunotherapy Total Market Size and Growth Rate from Consumption End

    • 5.5 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate, by Application

      • 5.5.1 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Small Cell Lung Cancer

      • 5.5.2 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Esophageal Cancer

      • 5.5.3 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Others

      • 5.5.4 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Non-Small Cell Lung Cancer

      • 5.5.5 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Urothelial Carcinoma

      • 5.5.6 China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Hepatocellular Carcinoma

    Chapter 6 China PD-1/PD-L1 Immunotherapy Market, by Region

    • 6.1 China PD-1/PD-L1 Immunotherapy Production Volume and Production Value, by Region

    • 6.2 China PD-1/PD-L1 Immunotherapy Sales Volume and Sales Value, by Region

    Chapter 7 North China PD-1/PD-L1 Immunotherapy Market Analysis

    • 7.1 North China PD-1/PD-L1 Immunotherapy Market, by Type

    • 7.2 North China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 8 Central China PD-1/PD-L1 Immunotherapy Market Analysis

    • 8.1 Central China PD-1/PD-L1 Immunotherapy Market, by Type

    • 8.2 Central China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 9 South China PD-1/PD-L1 Immunotherapy Market Analysis

    • 9.1 South China PD-1/PD-L1 Immunotherapy Market, by Type

    • 9.2 South China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 10 East China PD-1/PD-L1 Immunotherapy Market Analysis

    • 10.1 East China PD-1/PD-L1 Immunotherapy Market, by Type

    • 10.2 East China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 11 Northeast China PD-1/PD-L1 Immunotherapy Market Analysis

    • 11.1 Northeast China PD-1/PD-L1 Immunotherapy Market, by Type

    • 11.2 Northeast China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 12 Southwest China PD-1/PD-L1 Immunotherapy Market Analysis

    • 12.1 Southwest China PD-1/PD-L1 Immunotherapy Market, by Type

    • 12.2 Southwest China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 13 Northwest China PD-1/PD-L1 Immunotherapy Market Analysis

    • 13.1 Northwest China PD-1/PD-L1 Immunotherapy Market, by Type

    • 13.2 Northwest China PD-1/PD-L1 Immunotherapy Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Jiangsu HengRui Medicine Co Ltd

        • 14.1.1 Jiangsu HengRui Medicine Co Ltd Company Profile

        • 14.1.2 Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Bristol-Myers Squibb Company

        • 14.2.1 Bristol-Myers Squibb Company Company Profile

        • 14.2.2 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Sanofi SA

        • 14.3.1 Sanofi SA Company Profile

        • 14.3.2 Sanofi SA PD-1/PD-L1 Immunotherapy Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 AstraZeneca Plc

        • 14.4.1 AstraZeneca Plc Company Profile

        • 14.4.2 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 F Hoffmann-La Roche Ltd

        • 14.5.1 F Hoffmann-La Roche Ltd Company Profile

        • 14.5.2 F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 GlaxoSmithKline plc

        • 14.6.1 GlaxoSmithKline plc Company Profile

        • 14.6.2 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Chia Tai Tianqing Pharmaceutical Group Co Ltd

        • 14.7.1 Chia Tai Tianqing Pharmaceutical Group Co Ltd Company Profile

        • 14.7.2 Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Regeneron Pharmaceuticals Inc

        • 14.8.1 Regeneron Pharmaceuticals Inc Company Profile

        • 14.8.2 Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Innovent Biologics Inc

        • 14.9.1 Innovent Biologics Inc Company Profile

        • 14.9.2 Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 BeiGene Ltd

        • 14.10.1 BeiGene Ltd Company Profile

        • 14.10.2 BeiGene Ltd PD-1/PD-L1 Immunotherapy Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Eli Lilly & Company

        • 14.11.1 Eli Lilly & Company Company Profile

        • 14.11.2 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Novartis AG

        • 14.12.1 Novartis AG Company Profile

        • 14.12.2 Novartis AG PD-1/PD-L1 Immunotherapy Market Performance

        • 14.12.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 PD-1/PD-L1 Immunotherapy Industry Research Conclusions

    • 15.2 PD-1/PD-L1 Immunotherapy Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China PD-1/PD-L1 Immunotherapy Industry Market Size (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Production Volume, Production Value and Growth Rate of PD-L1 Inhibitors (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Production Volume, Production Value and Growth Rate of PD-1 Inhibitors (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Small Cell Lung Cancer (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Esophageal Cancer (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Non-Small Cell Lung Cancer (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Urothelial Carcinoma (2018-2029)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume, Sales Value and Growth Rate of Hepatocellular Carcinoma (2018-2029)

    • Figure North China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure Central China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure South China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure East China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure Northeast China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure Southwest China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure Northwest China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate from 2018-2029

    • Figure PD-1/PD-L1 Immunotherapy Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China PD-1/PD-L1 Immunotherapy Market Share by Type in 2018

    • Figure China PD-1/PD-L1 Immunotherapy Market Share by Type in 2023

    • Figure China PD-1/PD-L1 Immunotherapy Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Production Volume and Growth Rate of PD-L1 Inhibitors (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Production Volume and Growth Rate of PD-1 Inhibitors (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Market Share by Application in 2018

    • Figure China PD-1/PD-L1 Immunotherapy Market Share by Application in 2023

    • Figure China PD-1/PD-L1 Immunotherapy Total Market Size and Growth Rate from Consumption End

    • Figure China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Small Cell Lung Cancer (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Esophageal Cancer (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Others (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Non-Small Cell Lung Cancer (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Urothelial Carcinoma (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Market Size and Growth Rate of Hepatocellular Carcinoma (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Production Volume by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Production Volume Share by Region (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Production Volume Share by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Production Value by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Production Value Share by Region (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Production Value Share by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Sales Volume by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Sales Volume Share by Region (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Volume Share by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Sales Value by Region (2018-2023)

    • Table China PD-1/PD-L1 Immunotherapy Sales Value Share by Region (2018-2023)

    • Figure China PD-1/PD-L1 Immunotherapy Sales Value Share by Region (2018-2023)

    • Table North China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table North China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure North China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table North China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table North China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure North China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table Central China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table Central China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure Central China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table Central China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table Central China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure Central China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table South China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table South China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure South China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table South China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table South China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure South China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table East China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table East China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure East China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table East China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table East China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure East China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table Northeast China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table Northeast China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure Northeast China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table Northeast China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table Northeast China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure Northeast China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table Southwest China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table Southwest China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure Southwest China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table Southwest China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table Southwest China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure Southwest China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table Northwest China PD-1/PD-L1 Immunotherapy Production Volume by Type (2018-2023)

    • Table Northwest China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Figure Northwest China PD-1/PD-L1 Immunotherapy Production Volume Share by Type (2018-2023)

    • Table Northwest China PD-1/PD-L1 Immunotherapy Sales Volume by Application (2018-2023)

    • Table Northwest China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Figure Northwest China PD-1/PD-L1 Immunotherapy Sales Volume Share by Application (2018-2023)

    • Table Jiangsu HengRui Medicine Co Ltd Company Profile

    • Table Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Bristol-Myers Squibb Company Company Profile

    • Table Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Sanofi SA Company Profile

    • Table Sanofi SA PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table AstraZeneca Plc Company Profile

    • Table AstraZeneca Plc PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table F Hoffmann-La Roche Ltd Company Profile

    • Table F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline plc Company Profile

    • Table GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Chia Tai Tianqing Pharmaceutical Group Co Ltd Company Profile

    • Table Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Regeneron Pharmaceuticals Inc Company Profile

    • Table Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Innovent Biologics Inc Company Profile

    • Table Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table BeiGene Ltd Company Profile

    • Table BeiGene Ltd PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Eli Lilly & Company Company Profile

    • Table Eli Lilly & Company PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)

    • Table Novartis AG Company Profile

    • Table Novartis AG PD-1/PD-L1 Immunotherapy Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US